Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study
Conclusion Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.PMID:37963441 | DOI:10.1159/000535010 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 14, 2023 Category: Urology & Nephrology Authors: Lan Lan Yuxin Lin Binfeng Yu Yin Wang Hong Pan Huijing Wang Xiaowei Lou Xiabing Lang Qiankun Zhang Lie Jin Yi Yang Liang Xiao Jianghua Chen Fei Han Source Type: research
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study
Conclusion Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.PMID:37963441 | DOI:10.1159/000535010 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 14, 2023 Category: Urology & Nephrology Authors: Lan Lan Yuxin Lin Binfeng Yu Yin Wang Hong Pan Huijing Wang Xiaowei Lou Xiabing Lang Qiankun Zhang Lie Jin Yi Yang Liang Xiao Jianghua Chen Fei Han Source Type: research
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study
Conclusion Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.PMID:37963441 | DOI:10.1159/000535010 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 14, 2023 Category: Urology & Nephrology Authors: Lan Lan Yuxin Lin Binfeng Yu Yin Wang Hong Pan Huijing Wang Xiaowei Lou Xiabing Lang Qiankun Zhang Lie Jin Yi Yang Liang Xiao Jianghua Chen Fei Han Source Type: research
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study
Conclusion Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.PMID:37963441 | DOI:10.1159/000535010 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 14, 2023 Category: Urology & Nephrology Authors: Lan Lan Yuxin Lin Binfeng Yu Yin Wang Hong Pan Huijing Wang Xiaowei Lou Xiabing Lang Qiankun Zhang Lie Jin Yi Yang Liang Xiao Jianghua Chen Fei Han Source Type: research
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study
Conclusion Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.PMID:37963441 | DOI:10.1159/000535010 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 14, 2023 Category: Urology & Nephrology Authors: Lan Lan Yuxin Lin Binfeng Yu Yin Wang Hong Pan Huijing Wang Xiaowei Lou Xiabing Lang Qiankun Zhang Lie Jin Yi Yang Liang Xiao Jianghua Chen Fei Han Source Type: research
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study
Conclusion Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.PMID:37963441 | DOI:10.1159/000535010 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 14, 2023 Category: Urology & Nephrology Authors: Lan Lan Yuxin Lin Binfeng Yu Yin Wang Hong Pan Huijing Wang Xiaowei Lou Xiabing Lang Qiankun Zhang Lie Jin Yi Yang Liang Xiao Jianghua Chen Fei Han Source Type: research
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study
Conclusion Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.PMID:37963441 | DOI:10.1159/000535010 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 14, 2023 Category: Urology & Nephrology Authors: Lan Lan Yuxin Lin Binfeng Yu Yin Wang Hong Pan Huijing Wang Xiaowei Lou Xiabing Lang Qiankun Zhang Lie Jin Yi Yang Liang Xiao Jianghua Chen Fei Han Source Type: research
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study
Conclusion Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.PMID:37963441 | DOI:10.1159/000535010 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 14, 2023 Category: Urology & Nephrology Authors: Lan Lan Yuxin Lin Binfeng Yu Yin Wang Hong Pan Huijing Wang Xiaowei Lou Xiabing Lang Qiankun Zhang Lie Jin Yi Yang Liang Xiao Jianghua Chen Fei Han Source Type: research
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study
Conclusion Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.PMID:37963441 | DOI:10.1159/000535010 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 14, 2023 Category: Urology & Nephrology Authors: Lan Lan Yuxin Lin Binfeng Yu Yin Wang Hong Pan Huijing Wang Xiaowei Lou Xiabing Lang Qiankun Zhang Lie Jin Yi Yang Liang Xiao Jianghua Chen Fei Han Source Type: research
Diabetic Retinopathy and Chronic Kidney Disease: Associations and Comorbidities in a Large Diabetic Population: The Tongren Health Care Study
CONCLUSIONS: TD2 patients of older age and with higher body mass index, hypertension and dyslipidemia had a higher probability of being affected by CKD rather than DR, while those with a higher blood glucose level were more prone to DR than CKD.PMID:37952530 | DOI:10.1159/000535059 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 12, 2023 Category: Urology & Nephrology Authors: Li Qin Gao Can Can Xue Jing Cui Jie Xu Chun Zhang Dong Ning Chen Jost B Jonas Ya Xing Wang Source Type: research
Diabetic Retinopathy and Chronic Kidney Disease: Associations and Comorbidities in a Large Diabetic Population: The Tongren Health Care Study
CONCLUSIONS: TD2 patients of older age and with higher body mass index, hypertension and dyslipidemia had a higher probability of being affected by CKD rather than DR, while those with a higher blood glucose level were more prone to DR than CKD.PMID:37952530 | DOI:10.1159/000535059 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 12, 2023 Category: Urology & Nephrology Authors: Li Qin Gao Can Can Xue Jing Cui Jie Xu Chun Zhang Dong Ning Chen Jost B Jonas Ya Xing Wang Source Type: research
Virtual Pharmacy: An Integrated Collaborative Redesign Targeting Medication-related Problems in Patients with Chronic Kidney Disease
CONCLUSIONS: The iVRx is an acceptable and feasible clinical strategy. Our pilot program was associated with improved kidney care by increasing medication access for patients and avoiding potential harms associated with ADEs.PMID:37939689 | DOI:10.1159/000535094 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 8, 2023 Category: Urology & Nephrology Authors: Stephanie W Ong Abhijat Kitchlu David Z I Cherney Karen Leung Christopher T M Chan Source Type: research
Virtual Pharmacy: An Integrated Collaborative Redesign Targeting Medication-related Problems in Patients with Chronic Kidney Disease
CONCLUSIONS: The iVRx is an acceptable and feasible clinical strategy. Our pilot program was associated with improved kidney care by increasing medication access for patients and avoiding potential harms associated with ADEs.PMID:37939689 | DOI:10.1159/000535094 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 8, 2023 Category: Urology & Nephrology Authors: Stephanie W Ong Abhijat Kitchlu David Z I Cherney Karen Leung Christopher T M Chan Source Type: research
Virtual Pharmacy: An Integrated Collaborative Redesign Targeting Medication-related Problems in Patients with Chronic Kidney Disease
CONCLUSIONS: The iVRx is an acceptable and feasible clinical strategy. Our pilot program was associated with improved kidney care by increasing medication access for patients and avoiding potential harms associated with ADEs.PMID:37939689 | DOI:10.1159/000535094 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 8, 2023 Category: Urology & Nephrology Authors: Stephanie W Ong Abhijat Kitchlu David Z I Cherney Karen Leung Christopher T M Chan Source Type: research
Virtual Pharmacy: An Integrated Collaborative Redesign Targeting Medication-related Problems in Patients with Chronic Kidney Disease
CONCLUSIONS: The iVRx is an acceptable and feasible clinical strategy. Our pilot program was associated with improved kidney care by increasing medication access for patients and avoiding potential harms associated with ADEs.PMID:37939689 | DOI:10.1159/000535094 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 8, 2023 Category: Urology & Nephrology Authors: Stephanie W Ong Abhijat Kitchlu David Z I Cherney Karen Leung Christopher T M Chan Source Type: research
